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Aims/Introduction. Determining the prevalence of diabetes and its cardiovascular complications and all-cause mortality in older
chronic complex patients. Materials and Methods. We carried out a multicenter retrospective study and included a randomized
sample of 932 CCP people. We assessed the prevalence of diabetes according to World Health Organization criteria. Data included
demographics and functional, comorbidity, cognitive, and social assessment. Results. The prevalence of diabetes was 53% and
average age 81.16 ± 8.93 years. There were no significant differences in the survival of CCP patients with or without DM, with
or without ischaemic cardiopathy, and with or without peripheral vascular disease. The prognostic factors of all-cause mortality in
patients with DM were age ≥ 80 years [HR 1.47, 95% CI 1.02–2.13, 𝑝 0.038], presence of heart failure [HR 1.73, 95% CI 1.25–2.38,
𝑝 0.001], Charlson score [HR 1.20, 95% CI 1.06–1.36, 𝑝 0.003], presence of cognitive impairment [HR 1.73, 95% CI 1.24–2.40,
𝑝 0.001], and no treatment with statins [HR 1.49, 95%CI 1.08–2.04, 𝑝 0.038].Conclusions. We found high prevalence of DM among
CCP patients and the relative importance of traditional risk factors seemed to wane with advancing age. Recommendations may
include relaxing treatment goals, providing family/patient education, and enhanced communication strategies.
1. Introduction
The World Health Organization [1] has reported an increase
in the ageing population living with major chronic dis-
eases such as diabetes, dementia, cardiovascular disease, and
certain cancers, with most of the increase in developing
countries. Health experts have called this phenomenon the
“grey tsunami” [2] due to its impact on the health system.
Type-2 diabetes is one of the most common chronic diseases
affecting older people and its prevalence increases with age.
It has been estimated that the number of people over 65 with
diabetes will increase by 4.5-fold by 2050 [3]; and diabetes
is linked to higher mortality, reduced functional status,
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Several publications have described the spectrum of
comorbidities and functional impairment in ageing popula-
tions [5–7]. They emphasize a number of key features such
as the emergence of cognitive dysfunction and frailty that
can worsen adverse outcomes of diabetes such as emergency
visits, increased fall risk, and mortality. The main goal of
this study was to determine the prevalence of diabetes and
its cardiovascular complications and all-cause mortality in
complex chronic patients.
2. Materials and Methods
2.1. Study Population and Data Collection. This cohort study
(2013–2016) included 3,490 cases registered as complex
chronic patient enrolled in a large, integrated health primary
care teams in the Terres de l’Ebre health area in Catalonia
(Spain) with a sampling frame that included a randomized
sample of 932members.The source populationwas identified
from the Catalonian Health Institute Registry as of 1 January
2013 to 31 December 2014. We included subjects if they
met at least four of the following criteria: (1) age (≥65
years old), (2) chronic comorbidities (≥4), (3) psychosocial
disorders (cognitive impairment or psychological disorder
with functional disability), (4) geriatric conditions such as
functional disability (Barthel score < 55, living in assisted
living, in nursing home, or with in-home caregivers) or
recurrent falls or fall risk, (5) previous high healthcare use
(two hospitalizations not programmed for exacerbation of
chronic pathologies or three emergency department visits
in the last year), (6) ≥4 active medications in the last 6
months, and (7) living alone orwith a caregiver≥ 75 years old.
Established in January 2013, the registry is written, managed,
and updated by the nursing service in primary care using
the Shared Individual Intervention Plan [pla d’intervencio´
individualitzat compartit (PIIC)]. Follow-up of this cohort
members was initiated on 1 January 2013, and individuals
were censored at the first occurrence of death that had
occurred from any cause or at the end of the study (30
September 2016).
2.2. Variables. We collected data on demographic charac-
teristics and data related to clinical, functional, cognitive,
and social assessment. Comorbid conditions are defined
using standard outpatient and inpatient ICD-9 codes by
electronic data capture including pharmacy records, lab-
oratory data, and outpatient, emergency room, and hos-
pitalization diagnoses across all primary care centers and
hospital. Charlson comorbidity index, short version, was
scored. Polypharmacy was defined as five or more daily





VASCHAS-BLED scores were included. Pres-
ence of cognitive impairment, a disease-specific diagnosis
of cognitive impairment, without specification of subtype or
severity, was measured using the Pfeiffer test. The variable
definition includes recurrent falls or fall risk and pres-
ence of disability by Barthel score to assess dependence in
ADL.
Currently, 82% of people registered as CCP have available
clinical data in their PIIC report.
2.3. Criteria for theDefinition ofDiabetes. Diabetes (DM)was
diagnosed according to any of the following WHO criteria:
fasting plasma glucose (FPG) ≥ 7.0mmol/l (126mg/dl) or 75 g
oral glucose tolerance test (OGTT) with FPG ≥ 7.0mmol/l
(126mg/dl) and/or 2-hour plasma glucose ≥ 11.1mmol/l
(200mg/dl) or HbA1c ≥ 6.5%/48mmol/mol or random
plasma glucose ≥ 11.1mmol/l (200mg/dl) in the presence of
classical diabetes symptoms.
2.4. Statistical Analysis. Time to event analysis was per-
formed using the Kaplan-Meier and Log Rank test. To
estimate hazard ratios, mean survival time, and survival
probabilities, we used a multivariate Cox regression. Mul-
tivariate Cox proportional hazards regression models were
fitted to identify significant variables associated with the time
to death since diagnosis as CCP.The adjustedmodel included
the following baseline characteristics and the differences
observed between DM and no DM and predictive factors





VASC scales and active pharmacy. The analyses
were performed using IBM SPSS version 19.0.
3. Results
The baseline characteristics of the CCP group are shown
in Table 1. The prevalence of CCP was 1.94% in the total
population and 7.01% in those ≥60 years old. Diabetes had
been diagnosed in 53% of the CCP population, with an
average age of 81.16 ± 8.93 years, significantly younger (𝑝 <
0.001) than those CCP without DM, but with a higher
cardiovascular risk (𝑝 0.015), a higher risk of stroke (𝑝 <
0.001), more chronic conditions (𝑝 < 0.001), and a higher
number of prescribed drugs (𝑝 < 0.001), but a higher
Barthel score (𝑝 0.003) and lower prevalence of cognitive
impairment (𝑝 0.001).
The patients were divided into three major subgroups
defined jointly by age (<70, 70–79, and ≥80 years) and
prevalence of cardiovascular complications (Table 2). There
was a steady increase in the prevalence of cardiovascular
comorbidities such as atrial fibrillation and heart failure, cog-
nitive impairment, loss of autonomy in basic daily activities,
increased fall risk, and the all-causemortality rates associated
with ageing.Other traditional risk factors associatedwith dia-
betes such as hypertension, dyslipidemia, and macrovascular
complications such as ischaemic cardiopathy and peripheral
artery disease stayed the same or even decreased with ageing.
The average follow-up time was 2.75 years (95% CI
2.42–3.07). The all-cause mortality rate was 32.8% in DM
and 35.8% in non-DM patients. The incidence rate of death
was 13.1/100 person-years in DM and 11.7/100 person-years
in non-DM patients. There were no significant survival
differences (Figure 1) between those with or without DM,
with or without ischaemic cardiopathy (Figure 2), or with
or without peripheral artery disease. There was a significant
survival difference in the case of atrial fibrillation (𝑝 0.003)
(Figure 3) and heart failure (𝑝 < 0.001) (Figure 4). Table 3
shows number of deaths by decade of age.
In the CCP population with DM the prognostic mor-
tality factors identified by the multivariate method were
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Table 1: Baseline characteristics of CCP with and without diabetes.
CCP patients No diabetes Diabetes 𝑝
𝑁 (%) 438 (47.00%) 494 (53.00%)
Age (average ± SD) 84.22 ± 10.6 81.16 ± 8.0 <0.001
Percentage >80 years old
𝑛 (%) 340 (77.6%) 315 (63.8%) <0.001
Women 𝑛 (%) 236 (53.9%) 252 (51.0%) 0.394
CCP criteria number
(average ± SD) 3.85 ± 1.26 3.86 ± 1.12 0.955
Hypertension 𝑛 (%) 362 (80.4%) 422 (85.4%) 0.044
Dyslipidemia 𝑛 (%) 195 (44.5%) 326 (66.0%) <0.001
Atrial fibrillation 𝑛 (%) 176 (40.2%) 149 (30.2%) 0.002
Ischaemic cardiopathy 𝑛 (%) 87 (19.9%) 109 (22.1%) 0.422
Peripheral artery disease
𝑛 (%) 58 (13.2%) 91 (18.4%) 0.032
Chronic kidney insufficiency
< 30 mlClCr 43 (9.8%) 73 (14.7%) 0.042
Heart failure 𝑛 (%) 153 (34.9%) 150 (30.4%) 0.142
Charlson score
(average ± SD) 2.05 ± 1.30 2.95 ± 1.30 0.015
Stroke before CCP 𝑛 (%) 104 (23.7%) 96 (19.4%) 0.111






(average ± SD) 5.97 ± 2.38 7.14 ± 5.97 <0.001
HAS BLED score
(average ± SD) 2.88 ± 1.14 3.10 ± 1.05 0.077
Daily medications number
(average ± SD) 7.8 ± 3.29 9.80 ± 3.60 <0.001
Polypharmacy ≥ 4 𝑛 (%) 392 (89.5%) 484 (98%) <0.001
Polypharmacy ≥ 10 𝑛 (%) 142 (32.4%) 258 (52.2%) <0.001
Cognitive impairment 𝑛 (%) 179 (40.9%) 159 (32.2%) 0.006
Pfeiffer test score
(average ± SD) 3.43 ± 3.39 2.72 ± 3.13 0.001
Barthel score (average ± SD) 62.8 ± 32.41 69.02 ± 31.28 0.003
Barthel score < 60 𝑛 (%) 182 (41.6%) 161 (32.6%) 0.005
Fall risk 𝑛 (%) 103 (23.9%) 85 (17.2%) 0.018
Gijo´n score (average ± SD) 9.53 ± 5.12 10.46 ± 3.87 0.363
Antiaggregant treatment
𝑛 (%) 147 (33.6%) 238 (48.2%) <0.001
Anticoagulant treatment
𝑛 (%) 147 (33.6%) 123 (24.9%) 0.003
Statin treatment 𝑛 (%) 149 (34.0%) 274 (55.5%) <0.001
Proton pump inhibitor
treatment 𝑛 (%) 285 (65.1%) 358 (72.5%) 0.016
Selective serotonin reuptake
inhibitors (SSRIs) 𝑛 (%) 131 (29.9%) 149 (30.2%) 0.943
CNS depressant drugs 𝑛 (%) 249 (56.8%) 265 (53.6%) 0.356
Death 𝑛 (%) 157 (35.8%) 162 (32.8%) 0.334
age ≥ 80 years [HR 1.47, 95% CI 1.02–2.13, “𝑝 0.038”],
heart failure [HR 1.73, 95% CI 1.25–2.38, “𝑝 0.001”], the
Charlson score [HR 1.20, 95% CI 1.06–1.36, “𝑝 0.003”],









































































Figure 1: Kaplan-Meier estimates of survival during follow-up in
CCP with or without diabetes mellitus at baseline.
and no treatment with statins [HR 1.49, 95% CI 1.08–2.04,
“𝑝 0.038”].
We can define an epidemiological model with a high
prevalence of DM (53%) associated with classical risk factors
such as hypertension (84.1%), dyslipidemia (52.1%), atrial
fibrillation (37.9%), and stroke (28.3%) to which other risk
factors can be added such as age ≥80 years (70.2%), cognitive
impairment (44.1%), heart failure (35.6%), CNS depressant
drugs (56.9%), fall risk (23.2%), and the lowest Barthel score
(59, 95% CI 57.1–62.08), all of which increase the risk of
mortality.
4. Discussion
The registered prevalence of CCP in our study was higher
than in other developed countries [8] as was the prevalence
of diabetes mellitus in our CCP population [2, 9, 10]. The
frequency of comorbidity burden such as cognitive impair-
ment, polypharmacy, functional disability of basic activities
of daily living, and limited availability of caregiver support
may be a substantial problem in implementing amanagement
plan. A consensus has developed on how to treat older people
with diabetes [11, 12], but given that complicationsmay not be
present or may take many years to develop, efforts should be
adapted depending on the average remaining life expectancy
and degree of impairment of quality of life.
The authors believe a strategic change will involve mov-
ing away from “the diabetic patient with complications” to
“CCP with chronic comorbidities.”Therefore, while classically
diabetes mellitus has been associated with the development
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Table 2: Baseline characteristics of CCP patients according to age.
CCP patients <70 years old 70–79 years old ≥80 years old
𝑁 (% all) 93 (9.97%) 184 655
Age (average CI 95%) 61.39 (59.6–63.1) 75.6 (75.2–76.02) 87.5 (87.2–87.9)
Women 𝑛 (% group) 41/93 = 44.08% 82 (44.6%) 365 (55.7%)
CCP criteria number (average CI 95%) 2.9 (2.7–3.22) 3.69 (3.5–3.8) 4.02 (3.94–4.12)
Diabetes mellitus 𝑛 (% group) 53 (57.%) 125 (67.9%) 16 (48.2%)
Hypertension 𝑛 (% group) 63 (67.7%) 160 (87.0%) 551 (84.1%)
Dyslipidemia 𝑛 (% group) 55 (59.1%) 125 (67.9%) 341 (52.1%)
Atrial fibrillation 𝑛 (% group) 17 (18.3%) 60 (32.6%) 248 (37.9%)
Ischaemic cardiopathy 𝑛 (% group) 20 (21.5%) 43 (23.4%) 133 (20.3%)
Peripheral artery disease 𝑛 (% group) 17 (18.3%) 41 (22.3%) 91 (13.9%)
Chronic kidney insufficiency < 30 mlClCr 𝑛 (% group) 12 (12.9%) 24 (13.1%) 80 (12.2%)
Heart failure 𝑛 (% group) 17/93 = 18.27% 53 (28.8%) 233 (35.6%)
Charlson score (average CI 95%) 2.17 (1.87–2.47) 2.7 (2.5–2.9) 2.52 (2.42–2.63)





VASC score (average CI 95%) 4 (3.11–4.9) 5.17 (4.84–5.51) 5.03 (4.88–5.20)
Stroke risk/year (average CI 95%) 4.78 (3.55–6.02) 6.81 (6.2–7.4) 6.57 (6.27–6.87)
Daily medications number (average CI 95%) 9.21 (8.37–10.6) 10.1 (9.5–10.53) 8.5 (8.24–8.77)
Cognitive impairment 𝑛 (% group) 14 (15.1%) 35 (19.0%) 289 (44.1%)
Pfeiffer test score (average CI 95%) 1.40 (0.86–1.95) 1.53 (1.19–1.89) 3.71 (3.46–3.97)
Barthel score (average CI 95%) 82.8 (77.3–88.4) 80.67 (76.9–84.4) 59. (57.1–62.08)
Fall risk 𝑛 (% group) 5 (5.4%) 31 (16.8%) 152 (23.2%)
Antiaggregant treatment 𝑛 (% group) 30 (32.3%) 82 (44.6%) 273 (41.7%)
Anticoagulant treatment 𝑛 (% group) 25 (26.9%) 55 (29.9%) 175 (26.7%)
HAS BLED (average CI 95%) 2.93 (2.22–3.65) 3.06 (2.81–3.31) 2.96 (2.82–3.11)
Bleeding risk/year (average CI 95%) 5.18 (3.0–7.37) 4.89 (4.0–5.8) 4.95 (4.5–5.41)
Statin treatment 𝑛 (% group) 54 (58.1%) 118 (64.1%) 251 (38.3%)
CNS depressant drugs 𝑛 (% group) 44 (47.3%) 97 (52.7%) 373 (56.9%)
Death 𝑛 (% group) 12 (12.9%) 48 (26.1%) 259 (39.5%)
Average follow-up time 𝑛 (days CI 95%) 1348 (719–1977) 947 (901–993) 971 (825–1117)
of micro and macrovascular complications, with an ageing
population, it is not yet clear whether the presence of chronic
cardiovascular comorbidities or a higher risk of undergoing





should be approached as preventable and modifiable risk
factors (antiaggregant, statins) or as one more condition of
the “chronic complex patient” that needs to be controlled but
without benefits for cardiovascular risk.
Given that it is unknown how long the DM is running
and thatmost risk score tables exclude 75% of our CCP due to
their age, the use of such tables is pointless because we cannot
relate the cardiovascular complication rates to a risk score.
On the other hand, strategies to modify the incremental
tendency forDM involving the promotion of healthy lifestyles
(mainly associated with diet and physical activities) and the
detection of high risk patients are difficult to apply at this
vital stage. The priorities should be avoiding or lowering
the risk of complications (hypoglycemia, hyperglycemia, fall,
and polypharmacy) via an appropriate stratification using
the functional autonomy based on adaptations to individual
environments. The literature related to interventions for
lifestyle diseases in developing countries is very limited,
probably due to the multitude of possible health endpoints
and interventions, the multiple sources of the problem, and
the limited knowledge of means of changing individual and
population behavior [13–15].
In contrast with other studies [16], our results show that
the incidence of all-cause mortality and the prevalence of
cardiovascular diseases donot differ significantly amongCCP
with and without DM. The data about deaths related to
diabetes are confusing and come from different age cohorts:
according to the World Health Organization, 43% of all
deaths due to high blood glucose occur before the age of 70
[17]; and the proportion of deaths attributable to diabetes
was estimated to be 11.5% in the United States [18, 19]. In
our study the mortality rate due to diabetes was 17%, and
<70 years old is when the difference in mortality is higher
between DM and no DM. This fact supports our thought of
a different epidemiologic profile in this group of population.
However, we found risk factors associated with ageing such
as cognitive impairment and heart failure that have been
described previously as prognostic factors for mortality [5–7]
in the CCP population. This supports the idea that all-cause
mortality is more affected by ageing factors than by specific








































































Figure 2: Kaplan-Meier estimates of survival during follow-up in






































































All-cause mortality with atrial fibrillation
Figure 3: Kaplan-Meier estimates of survival during follow-up in
CCP with or without atrial fibrillation at baseline.
All-cause mortality with heart failure
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Figure 4: Kaplan-Meier estimates of survival during follow-up in
CCP with and without heart failure at baseline.




𝑁 (%) 𝑝 All
<70
(𝑛 93) 9 (17.0%) 3 (7.5%) 0.150 12 (12.9%)
70–79
𝑛 (184) 32 (25.6%) 16 (27.1%) 0.480 48 (26.1%)
80–89
𝑛 (435) 74 (31.6%) 72 (35.8%) 0.361 146 (33.6%)
≥90
𝑛 (220) 47 (57.3%) 66 (47.8%) 0.209 113 (51.4%)
Total
(𝑛 932) 162 (32.8%) 157 (35.8%) 0.181 319 (34.2%)
complications of DM. Likewise the incidence of DM in this
CCP population may be more of a consequence of the ageing
process than an independent disease. The comorbidities may
drive all-cause mortality and the contribution of diabetes in
the presence of complex chronic diseases to overall mortality
seems to be only minimal.
Despite the above, we should not underestimate the
importance of evaluating and treating cardiovascular risk
given that it plays a key role in cardiovascular prevention in
all national and international guidelines [20], mainly among
patients with a high level of functional dependence. The
relative importance of traditional risk factors seems to wane
with advancing age [21] and for this reason; we emphasize
the importance of redefining the care strategy and adapting
it to comorbidities and functional autonomy rather than
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achieving excellent levels of glycated haemoglobin or total
cholesterol.
The limitations of the present approach are related to the
possibility of overestimating the prevalence of DM among
the CCP population as a consequence of the definition
criteria despite being a randomized sample; not knowing
the duration of DM in order to prevent complications; and
perhaps the frequency with which diabetes is listed as the
underlying cause of death is not a reliable indicator of
its contribution to the mortality profile. Also, we need to
determine accurately whether diabetes was the underlying
cause of death or was only an associated cause of death.
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